FDA 483 - Lupin Limited - November 23, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The inspection at Lupin Limited Unit I in Mandideep, India, revealed significant deficiencies in quality control, data integrity, and manufacturing practices. Observations included inadequate investigations into out-of-specification results, lack of proper computer system controls, failure to maintain complete records, and deficiencies in engineering practices and equipment calibration. These issues indicate a systemic breakdown in ensuring the quality and integrity of pharmaceutical products.
ID · 9526924e-9742-43cf-b424-a50ea10b302e